Through ongoing quarterly targeted medication counseling follow-up sessions, the pharmacist may identify ART noncompliance.
Genevieve Regal, PharmD, HC-MBA
Advertisement
Articles by Genevieve Regal, PharmD, HC-MBA
On August 23, 2018, the FDA approved lanadelumab-flyo (Takhzyro; Shire) for the prophylaxis treatment and prevention of hereditary angioedema (HAE) in patients 12 years or older.
Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.
Advertisement
Latest Updated Articles
FDA Biosimilar Plan Offers Employers Saving Strategy SolutionPublished: July 19th 2018 | Updated:
Takhzyro for Hereditary AngioedemaPublished: November 15th 2018 | Updated:
The Pharmacist’s Role in Maximizing HIV Antiretroviral TherapyPublished: January 22nd 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
2
CHEST 2025: Improving Access to Chronic Cough Treatment Through a Digital Therapeutic Solution
3
What to Know About the Latest Pediatric Respiratory Infections
4
Addressing Substance Abuse Requires Heightened Awareness
5
